Workflow
Tempus Ai,Inc.(TEM)
icon
Search documents
Why Tempus Ai Stock Is Skyrocketing Today
The Motley Fool· 2025-01-21 20:40
Stock Performance - Tempus Ai stock surged 35 8% as of 3 15 p m ET and had been up as much as 41 8% earlier in the day [1] - Despite the recent surge Tempus Ai is up just 16% over the last year and still down roughly 40% from its November high [7] Catalysts for Stock Surge - Nancy Pelosi purchased 50 call options for Tempus Ai stock with a strike price of $20 per share and a trade value between $50 000 and $100 000 [3] - Pelosi recorded gains of 70 9% on her stock trades in 2024 far exceeding the S&P 500's 25% gain [4] - Tempus Ai launched a new AI-powered olivia healthcare app designed to organize patient health data and generate care insights [5][6] Financial and Business Outlook - Tempus Ai anticipates revenue growth of 30% annually reaching $693 million in 2024 [8] - The rollout of the new software platform could support strong growth in 2025 [8]
Tempus AI Has A High Probability Of Profitability In 2025
Seeking Alpha· 2025-01-21 20:14
Company Performance - Tempus AI Inc (NASDAQ: TEM) has provided preliminary Q4 2024 results indicating a 30% year-over-year growth rate at the top line [1] - The Ambry deal is expected to close in Q1 2025, with management anticipating positive outcomes [1] Analyst Background - Michael Del Monte is a buy-side equity analyst with over 5 years of industry experience [1] - Prior to investment management, Michael spent over a decade in professional services across industries including O&G, OFS, Midstream, Industrials, Information Technology, EPC Services, and consumer discretionary [1] - Michael employs a macro-value-oriented approach to investment analysis, leveraging cross-industry insights for investment recommendations [1]
Tempus AI jumps almost a third on health app launch
Proactiveinvestors NA· 2025-01-21 18:36
About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...
Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update
Seeking Alpha· 2025-01-15 09:53
Company Overview - Tempus AI is a leading player in the fast-growing healthcare AI industry [1] - The company's proprietary data model aims to break down barriers across the industry to deliver personalized healthcare treatment [1] - Applications of the company's technology are still in early stages [1] Industry Context - The healthcare AI industry is experiencing rapid growth [1] - The industry is focused on developing solutions for personalized healthcare treatment [1]
TEM Stock Declines Following Preliminary Q4 Sales Miss
ZACKS· 2025-01-14 14:11
Tempus AI, Inc. (TEM) , a leader in precision medicine and AI-enabled diagnostics, announced preliminary financial results for the fourth quarter and fiscal 2024. The company also provided additional details at the 43rd Annual J.P. Morgan Healthcare Conference, including forward-looking plans for 2025, emphasizing growth across genomics, data services and applications. The company's shares fell 13.8% on Jan. 13 as the top line missed market expectations.Tempus plans to report its complete fourth-quarter and ...
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
ZACKS· 2025-01-09 15:01
Collaboration Between Tempus and Genialis - Tempus AI Inc (TEM) announced a multi-year collaboration with Genialis to leverage Tempus' multimodal dataset for developing RNA-based algorithms across cancer types [1] - The partnership combines Tempus' expertise in clinical and molecular data with Genialis' AI-driven analytics to improve diagnostics and personalized treatments in precision medicine [2] - The collaboration enhances Tempus' offerings in precision medicine through AI-driven RNA biomarker development, potentially attracting more partnerships and increasing revenue potential [3] Impact on TEM Stock and Financials - Following the announcement, TEM shares declined 3.5% to close at $37.49, with a 6.9% loss over the past year compared to the industry's 10.5% decline [2] - TEM currently has a market capitalization of $6.12 billion, with Zacks Consensus Estimate projecting fiscal 2024 revenues of $698.5 million, indicating 117.8% growth from fiscal 2023 [4] Genialis' AI-Powered Model and Clinical Algorithms - Genialis developed an AI-powered model using data from around 1 million RNA-sequencing samples to generate precise biomarker algorithms for improving drug development [5][6] - The collaboration allows Genialis to use Tempus' de-identified patient data to validate biomarkers, speeding up the development of clinical algorithms [7] - Tempus' multimodal dataset played a key role in developing Genialis krasID, the first commercially available algorithm for identifying cancer patients who benefit from KRAS inhibition [8] Industry Prospects for AI in Healthcare - The global AI in healthcare market was estimated at $19.27 billion in 2023 and is expected to grow at a CAGR of 38.5% from 2024 to 2030 [9] - The adoption of digital technologies in healthcare is driven by the need to reduce costs and enhance patient-care services, boosting the growth of AI in the healthcare market [10] TEM's Zacks Rank and Peer Comparison - TEM carries a Zacks Rank 2 (Buy) at present [11] - Masimo (MASI) has an estimated growth rate of 11.8% for 2025, with shares rising 31.7% against the industry's 1% decline in the past six months [11][12] - Accuray (ARAY) has an estimated growth rate of 1200% for 2025, with shares gaining 8.8% against the industry's 1% decline in the past six months [12][13] - Abbott Laboratories (ABT) has an estimated earnings growth rate of 10% for 2025, with shares rising 8.5% in the past six months compared to the industry's 7.2% growth [13]
Tempus AI Stock Surges 23% in 6 Months: Should You Snap It Up Now?
ZACKS· 2025-01-07 17:31
Tempus AI (TEM) , an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. The company’s stock has demonstrated impressive growth over the past six months, fueled by investor enthusiasm for AI-driven advancements and the company’s interesting financial performance.In the past six months, the stock has rallied 22.8%, outperforming the 16.5% rise of the Medical Info Systems industry and the benchmark’s 6.8% increase. In ...
Tempus AI Stock Plunges 28.9% in Three Months: What's Next?
ZACKS· 2024-12-24 17:31
Tempus AI, Inc.’s (TEM) investors have been encountering short-term losses from the stock of late. Shares of the Chicago, IL-based healthcare technology company focused on adopting artificial intelligence (AI) to advance precision medicine and patient care have plunged 28.9% in the past three months, underperforming the industry’s 0.6% gain. In the same time frame, the stock underperformed the sector and S&P 500’s 12.4% loss and 5.1% growth, respectively.Two major developments from TEM this month include th ...
Tempus AI: A Potential Double-Bagger After Recent Pullback
MarketBeat· 2024-12-20 13:45
Tempus AI TodayTEMTempus AI$33.03 -1.26 (-3.67%) 52-Week Range$22.89▼$79.49Price Target$56.00Add to WatchlistIn mid-August, around two months after Tempus AI’s NASDAQ: TEM initial public offering (IPO), the stock was up a marvelous 93%. However, shares have experienced wild volatility and are now 8% below their opening price of $37 as of the Dec. 18 close. Overall, Wall Street analysts seem to believe shares have fallen much too far. The average price target implies shares could rise 74% from their Dec. 18 ...
Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Seeking Alpha· 2024-12-18 03:42
It is often difficult for investors to gauge success for recent IPOs, as there are many factors to take into consideration. In the event of Tempus AI (NASDAQ: TEM ), there are many long-term drivers to love aboutAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than f ...